AimedBio, a
biotech developing novel antibody-drug conjugates (ADCs), announced it has
passed Korea’s rigorous technical evaluation for listing on the KOSDAQ under
the country’s tech-special listing track. The company received “A” grades from
both Korea Exchange-designated evaluation institutions, demonstrating the
strength of its pipeline and market potential. AimedBio now moves into formal
listing preparations, with a preliminary filing planned for later this year.
Mirae Asset Securities is serving as lead underwriter.
Recent R&D milestones and scientific progress laid the groundwork for the
evaluation. Backed by strong science and a focus on high unmet medical needs, AimedBio’s
differentiated programs are gaining increasing external recognition. In 2024,
the company signed its first licensing deal, followed by a collaboration and
license agreement with SK Plasma earlier this month for a second ADC program.
Additional promising candidates are advancing through the pipeline, further
underscoring the depth of its proprietary technology. AimedBio has also secured
five national grants from Korea’s KDDF program, reinforcing the competitiveness
of its R&D.
Founded in 2018 as a spin-off from Samsung Medical Center, AimedBio received
strategic investment from the Samsung Life Science Fund—the first and only
biotech in Korea to do so. The company continues to advance a differentiated
pipeline using its proprietary in-house technologies.
“This evaluation marks an important step toward our KOSDAQ listing and
demonstrates market confidence in our programs and vision” said CEO Nam-Gu Her.
“We look forward to entering our next phase of growth as an emerging player in
next-generation cancer therapeutics.”